Fc engineering approaches to enhance the agonism and effector functions of an Anti-OX40 antibody

Journal of Biological Chemistry

Volumn 291, Issue 53, 2016, Pages 27134-27146

  Zhang, Di ^a   Goldberg, Monica V ^a,b   Chiu, Mark L ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; BINS; CYTOTOXICITY; TUMORS;

AGONIST ACTIVITY; AGONISTIC ACTIVITY; ANTI-TUMOR ACTIVITIES; ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITIES; CANCER IMMUNOTHERAPY; COMPLEMENT-DEPENDENT CYTOTOXICITIES; RECEPTOR BINDING; TUMOR NECROSIS FACTOR RECEPTORS;

ANTIBODIES;

FC RECEPTOR GAMMA IIIA; FC RECEPTOR IIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2 DELTA FC; LYMPHOCYTE ANTIBODY; OX40 ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; CD134 ANTIGEN; FC RECEPTOR; FCGR2B PROTEIN, HUMAN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG PROTEIN BINDING; GENE SILENCING; HEXAMERIZATION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; STRUCTURE ANALYSIS; AGONISTS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL CULTURE; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; METABOLISM; NEOPLASMS; PROTEIN ENGINEERING;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELLS, CULTURED; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MACROPHAGES; NEOPLASMS; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, IGG; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 85007572122     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.757773     Document Type: Article

References (34)

1. Mellman, I., Coukos, G., and Dranoff, G. (2011) Cancer immunotherapy comes of age. Nature 480, 480-489
2. Chen, L., and Flies, D. B. (2013) Molecular mechanisms of T cell costimulation and co-inhibition. Nat. Rev. Immunol. 13, 227-242
3. Schaer, D. A., Hirschhorn-Cymerman, D., and Wolchok, J. D. (2014) Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J. Immunother. Cancer 2, 7
4. + T cells. J. Immunol. 172, 7306-7314
5. Gramaglia, I., Weinberg, A. D., Lemon, M., and Croft, M. (1998) Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161, 6510-6517
6. Pollok, K. E., Kim, Y. J., Zhou, Z., Hurtado, J., Kim, K. K., Pickard, R. T., and Kwon, B. S. (1993) Inducible T cell antigen 4-1BB: analysis of expression and function. J. Immunol. 150, 771-781
7. Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjo, M., Marsh, H. C., and Keler, T. (2015) Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. J. Immunother. Cancer 3, 37
8. Khalil, M., and Vonderheide, R. H. (2007) Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther. 2, 61-65
9. Mangsbo, S. M., Broos, S., Fletcher, E., Veitonmäki, N., Furebring, C., Dahlén, E., Norlén, P., Lindstedt, M., Tötterman, T. H., and Ellmark, P. (2015) The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin. Cancer Res. 21, 1115-1126
10. He, L. Z., Prostak, N., Thomas, L. J., Vitale, L., Weidlick, J., Crocker, A., Pilsmaker, C. D., Round, S. M., Tutt, A., Glennie, M. J., Marsh, H., and Keler, T. (2013) Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J. Immunol. 191, 4174-4183
11. Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., Ross, S., Vernes, J. M., Lu, Y., Adams, C., Offringa, R., et al. (2011) An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19, 101-113
12. Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., and Brogdon, J. L. (2013) Activating Fcγ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210, 1685-1693
13. Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., and Brogdon, J. L. (2014) OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol. Cell Biol. 92, 475-480
14. Morris, N. P., Peters, C., Montler, R., Hu, H. M., Curti, B. D., Urba, W. J., and Weinberg, A. D. (2007) Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol. Immunol. 44, 3112-3121
15. Li, F., and Ravetch, J. V. (2011) Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030-1034
16. White, A. L., Chan, H. T., Roghanian, A., French, R. R., Mockridge, C. I., Tutt, A. L., Dixon, S. V., Ajona, D., Verbeek, J. S., Al-Shamkhani, A., Cragg, M. S., Beers, S. A., and Glennie, M. J. (2011) Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754-1763
17. Li, F., and Ravetch, J. V. (2012) Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc. Natl. Acad. Sci. U.S.A. 109, 10966-10971
18. Xu, Y., Szalai, A. J., Zhou, T., Zinn, K. R., Chaudhuri, T. R., Li, X., Koopman, W. J., and Kimberly, R. P. (2003) FcγRs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J. Immunol. 171, 562-568
19. Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., and Lambrecht, B. N. (2014) The function of Fcγ receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14, 94-108
20. Chu, S. Y., Vostiar, I., Karki, S., Moore, G. L., Lazar, G. A., Pong, E., Joyce, P. F., Szymkowski, D. E., and Desjarlais, J. R. (2008) Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Mol. Immunol. 45, 3926-3933
21. Mimoto, F., Katada, H., Kadono, S., Igawa, T., Kuramochi, T., Muraoka, M., Wada, Y., Haraya, K., Miyazaki, T., and Hattori, K. (2013) Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131). Protein Eng. Des. Sel. 26, 589-598
22. White, A. L., Chan, H. T., French, R. R., Willoughby, J., Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G., Dodhy, A., Polak, M. E., Potter, E. A., Ardern-Jones, M. R., Verbeek, J. S., Johnson, P. W., Al-Shamkhani, A., et al. (2015) Conformation of the human immunoglobulin γ2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 27, 138-148
23. Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J., van de Winkel, J. G., Wilson, I. A., Koster, A. J., Taylor, R. P., Saphire, E. O., et al. (2014) Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260-1263
24. de Jong, R. N., Beurskens, F. J., Verploegen, S., Strumane, K., van Kampen, M. D., Voorhorst, M., Horstman, W., Engelberts, P. J., Oostindie, S. C., Wang, G., Heck, A. J., Schuurman, J., and Parren, P. W. (2016) A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 14, e1002344
25. Arch, R. H., and Thompson, C. B. (1998) 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB. Mol. Cell. Biol. 18, 558-565
26. Kawamata, S., Hori, T., Imura, A., Takaori-Kondo, A., and Uchiyama, T. (1998) Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-κB activation. J. Biol. Chem. 273, 5808-5814
27. Simons, P. J., Boon, L., Luo, J., Brezski, R. J., and Goldberg, M. (December 25, 2014) Humanized anti-CD134 (OX40) antibodies and uses thereof. U. S. Patent 2014/0377284
28. Li, F., and Ravetch, J. V. (2012) A general requirement for FcγRIIB coengagement of agonistic anti-TNFR antibodies. Cell Cycle 11, 3343-3344
29. Rankin, C. T., Veri, M. C., Gorlatov, S., Tuaillon, N., Burke, S., Huang, L., Inzunza, H. D., Li, H., Thomas, S., Johnson, S., Stavenhagen, J., Koenig, S., and Bonvini, E. (2006) CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 108, 2384-2391
30. Veri, M. C., Gorlatov, S., Li, H., Burke, S., Johnson, S., Stavenhagen, J., Stein, K. E., Bonvini, E., and Koenig, S. (2007) Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121, 392-404
31. Luo, Y., Lu, Z., Raso, S. W., Entrican, C., and Tangarone, B. (2009) Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcγ receptors. mAbs 1, 491-504
32. Moran, A. E., Kovacsovics-Bankowski, M., and Weinberg, A. D. (2013) The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. 25, 230-237
33. Xiao, X., Balasubramanian, S., Liu, W., Chu, X., Wang, H., Taparowsky, E. J., Fu, Y. X., Choi, Y., Walsh, M. C., and Li, X. C. (2012) OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat. Immunol. 13, 981-990
34. Indik, Z. K., Park, J. G., Hunter, S., and Schreiber, A. D. (1995) The molecular dissection of Fcγ receptor mediated phagocytosis. Blood 86, 4389-4399